This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: University of Kansas, Silvergate Pharmaceuticals Inc., Silvergate Pharmacauticals, Inc.. Active years: 2014-2018.
Company Filing History:
3 out of 571 
2 out of 26 
1 out of 1 Years Active: 2014-2018
Title: The Innovations of Frank Segrave
Introduction
Frank Segrave is an accomplished inventor based in Dublin, Ohio. He has made significant contributions to the field of pharmaceuticals, particularly in the development of enalapril compositions. With a total of three patents to his name, Segrave's work has had a notable impact on the treatment of various cardiovascular diseases.
Latest Patents
Segrave's latest patents focus on stable enalapril powder compositions for oral liquid formulations. These compositions are designed for the treatment of diseases such as hypertension, heart failure, and asymptomatic left ventricular dysfunction. The methods provided in these patents highlight the importance of effective oral liquid formulations in managing these health conditions.
Career Highlights
Throughout his career, Frank Segrave has worked with reputable organizations, including the University of Kansas Medical Center Research Institute and Silvergate Pharmaceuticals Inc. His experience in these institutions has allowed him to refine his expertise in pharmaceutical research and development.
Collaborations
Segrave has collaborated with notable colleagues, including Lian G. Rajewski and Roger A. Rajewski. These partnerships have contributed to the advancement of his research and the successful development of his patented innovations.
Conclusion
Frank Segrave's contributions to the field of pharmaceuticals, particularly through his patents on enalapril compositions, demonstrate his commitment to improving healthcare outcomes. His work continues to influence the treatment of cardiovascular diseases, showcasing the importance of innovation in medicine.